

STERLING BIOTECH LIMITED

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE FIRST QUARTER ENDED 31 MARCH 2012

PART I

(Rs. in Lacs)

Sr. No.	Particulars	Quarter ended 31/03/2012	Previous Quarter ended 31/12/2011	Corresponding Quarter ended 31/03/2011	Twelve Months ended 31/12/2011
		Unaudited	(Ref. Note No.5)	Unaudited	Audited
1	Income from Operations				
	a) Net Sales/Income from Operations	20,752.35	32,657.78	43,828.15	166,195.39
	b) Other Operating Income	228.90	184.34	326.35	930.78
	c) Total Income from Operations	20,981.25	32,842.12	44,154.50	167,126.17
2	Expenses				
	a) Cost of materials consumed	18,227.17	29,570.69	19,871.48	102,799.60
	b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2,930.64)	(10,993.18)	(4,688.02)	(14,836.69)
	d) Employee benefits expense	1,357.82	1,332.87	1,178.92	5,056.56
	e) Depreciation and amortization expense	6,362.44	6,413.11	6,036.41	25,709.95
	f) Other Expenses	1,232.73	2,463.52	7,648.79	9,435.24
	g) Total Expenses	24,249.52	28,787.01	30,047.58	128,164.66
3	Profit / (Loss) from Operations before Other Income and finance Costs (1-2)	(3,268.27)	4,055.11	14,106.92	38,961.51
4	Other Income	0.00	0.00	0.00	0.00
5	Profit / (Loss) from Ordinary activities before finance costs (3+4)	(3,268.27)	4,055.11	14,106.92	38,961.51
6	Finance Costs	10,371.23	7,267.12	6,317.64	27,043.08
7	Profit / (Loss) from Ordinary Activities after finance costs but before tax (5-6)	(13,639.50)	(3,212.01)	7,789.28	11,918.43
8	Tax expense				
	a) Current	0.00	(2,245.83)	1,560.00	570.02
	b) Deferred	(4,425.00)	(1,616.29)	1,100.00	300.01
	c) Total	(4,425.00)	(3,862.12)	2,660.00	870.03
9	Net Profit / (Loss) from Ordinary Activities after tax (7-8)	(9,214.50)	650.11	5,129.28	11,048.40
10	Extraordinary Items	0.00	(8,073.29)	0.00	(9,135.22)
11	Net Profit / (Loss) for the period (9+10)	(9,214.50)	(7,423.18)	5,129.28	1,913.18
12	Prior year adjustment	0.00	81.69	0.00	81.69
13	Profit available for appropriation	(9,214.50)	(7,341.49)	5,129.28	1,994.87
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,678.74	2,678.74	2,678.74	2,678.74
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				246,410.14
16.i	Earnings Per Share (EPS) (before extraordinary items) (F.V. of Re.1/- each) (not annualised)				
	a) Basic	(3.44)	0.24	1.91	4.12
	b) Diluted	(3.05)	0.21	1.70	3.65
16.ii	Earnings Per Share (EPS) (after extraordinary items) (F.V. of Re.1/- each) (not annualised)				
	a) Basic	(3.44)	(2.77)	1.91	0.71
	b) Diluted	(3.05)	(2.45)	1.70	0.63

STERLING BIOTECH LIMITED

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

Select Information for the Quarter ended 31 March 2012

PART II

Sr. No.	Particulars	Quarter ended 31/03/2012	Previous Quarter ended 31/12/2011	Corresponding Quarter ended 31/03/2011	Twelve Months ended 31/12/2011
A	PARTICULARS OF SHAREHOLDING				
1	Public Shareholding				
	- Number of shares	131,861,090	131,861,090	133,666,531	131,861,090
	- Percentage of shareholding	49.23%	49.23%	49.90%	49.23%
2	Promoters and Promoter Group Shareholding				
	a) Pledged/Encumbered				
	Number of shares	50,816,835	50,816,835	21,428,340	50,816,835
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	55.94%	55.94%	24.07%	55.94%
	Percentage of shares (as a % of the total share capital of the Company)	18.97%	18.97%	8.00%	18.97%
	b) Non-encumbered				
	Number of shares	40,023,300	40,023,300	67,606,354	40,023,300
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	44.06%	44.06%	75.93%	44.06%
	Percentage of shares (as a % of the total share capital of the Company)	14.94%	14.94%	25.24%	14.94%

Sr. No.	Particulars	Quarter ended 31/03/2012
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the Quarter	0
	Received during the quarter	8
	Disposed of during the quarter	8
	Remaining unresolved at the end of the quarter	0

Notes:

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- 2 The above Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 15 May 2012.
- 3 The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 31 March 2012
- 4 The Company has Overseas Subsidiary and there are no business operations in the subsidiary company.
- 5 The figures of the Previous Quarter ended on 31 December 2011 are the balancing figures between Audited figures in respect of the full Financial Year ended on 31 December 2011 and the published year to date figures upto the third quarter ended on 30 September 2011.
- 5 Previous period figures have been regrouped/reclassified, wherever necessary.

**For and on Behalf of
STERLING BIOTECH LIMITED**

Place : Mumbai
Date : 15 May 2012.

**Chetan J. Sandesara
Joint Managing Director**